How much funding has Prolifagen raised?

Prolifagen has disclosed $3M raised across 1 round.

Where is Prolifagen headquartered?

Prolifagen is headquartered in Doylestown, US.

Prolifagen

Doylestown, US · Founded 2025 · Delaware corporation

Find your way into Prolifagen

139 people in our graph share verified history with the Prolifagen team — schools, employers, funds. One of them is your warm intro.

Jamy Gannoeunlockedknows Michael Behr · together at Orthalign (overlapped)

×11knows the team · via Broad Street Angels

Prolifagen develops microRNA (miR) technology to stimulate the regeneration of heart muscle damaged by myocardial infarction, aiming to prevent scar tissue formation and restore cardiac function. The company targets physicians and heart attack patients seeking solutions to prevent heart failure and recurrent cardiac events.

Biotech Deep Tech Longevity Medical Devices

Founders & leadership

Andreas BaderExecutive

William HoustonExecutive

Michael Behr Chief Executive OfficerMichael Behr is an executive with experience building and commercializing life science startups. He leads Prolifagen, which develops microRNA technology to stimulate heart muscle regeneration following myocardial infarction.

Claudine BruckNamed on SEC filing

Board

M. Alexander ShawBoard director

Reported raises · per SEC filings

Form D private placements

$3M disclosed across 1 round · 2025

▶$3MraisedSep 2025 · 6 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

M. Alexander ShawDirector
Andreas BaderExecutive Officer
William HoustonExecutive Officer
Michael BehrExecutive Officer, Director
Claudine BruckExecutive Officer, Director

Amount sold: $3M
First sale: Sep 2025
Incorporated: Corporation, Delaware, 2025
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap

Exagen11 shared keywordsExagen develops diagnostic and monitoring tests for autoimmune diseases, including tools to distinguish connective tissue disease and assess lupus prognosis and progression. The company serves healthcare professionals and patients with chronic autoimmune conditions.

Nivagen6 shared keywordsNivagen provides drug product development services, guiding pharmaceutical companies through the full lifecycle from concept to commercialization, including traditional NDAs, 505(b)(2)s, and complex generics. The company serves pharmaceutical and biotech firms seeking to bring innovative drug products to market with intellectual property protection and accelerated timelines.

Biogen Idec6 shared keywordsBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.

Companies competing with Prolifagen for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Leadership - Prolifagen Incorporatedprolifagen.com · Jun 2025

Prolifagen Therapeutics - Medtech Alertmedtechalert.com · Sep 2022

Prolifagen LLC Wins “Best in Show at Philadelphia 1st Pitch Life Science Competitionglobenewswire.com · Mar 2018

Frequently asked questions

What does Prolifagen do?: Prolifagen develops microRNA (miR) technology to stimulate the regeneration of heart muscle damaged by myocardial infarction, aiming to prevent scar tissue formation and restore cardiac function. The company targets physicians and heart attack patients seeking solutions to prevent heart failure and recurrent cardiac events.
How much funding has Prolifagen raised?: Prolifagen has disclosed $3M raised across 1 round.
Where is Prolifagen headquartered?: Prolifagen is headquartered in Doylestown, US.